SOTIO Doses First Patient in AURELIO-05 Phase II Trial of Nanrilkefusp Alfa in Combination with Cetuximab

SOTIO Biotech announced that the first patient was dosed in its Phase II AURELIO-05 combination trial of nanrilkefusp alfa, an IL-15 superagonist, and cetuximab in patients with colorectal cancer.